Alberta Biosimilar Initiative

The Alberta government, under the Alberta Biosimilars Initiative, is changing the funding of select biologic medications for adult patients on Alberta government sponsored drug plans

Alberta spent more than $238 million in the 2018 to 2019 fiscal year on biologic drugs and these costs are increasing every year. Costs per patient for originator biologics can be more than $25,000 per patient per year, with biosimilar versions costing up to 50 per cent less than originator biologics.

Alberta is implementing the Biosimilar Initiative which will save approximately $30 million annually that can be invested into other health care services for Albertans.

For more information: Click HERE